SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access

NCT02834884 · tracked via the Priya Life Science Poland tracker

Sponsor

European Organisation for Research and Treatment of Cancer - EORTC

Phase

Observational

Started

2017-05-03

Last updated

2026-06-24

Condition(s) studied

All Tumor Types

Investigational drug(s) / intervention(s)

RP-1828 IMMUcanRP-1759 AYA/TYARP-1843 ArcagenRP-1920 BioRadon2148 MRD

RP-1828 IMMUcan: WES, lcWGS and RNAseq, multiplex IF and IMC

RP-1759 AYA/TYA: WES, RNAseq and EPIC array

RP-1843 Arcagen: NGS panel

RP-1920 BioRadon: NGS panel

2148 MRD: ctDNA detection and WES

Study summary

SPECTA is a quality assured platform for collecting clinicopathologically annotated biological material, imaging data, operative images, environmental assessment, questionnaires as well as patient-reported outcomes from cancer patients to support biospecimen-based translational research and clinical cancer research, including biomarker discovery to improve the understanding of tumor biology and cancer patients care.

Eligibility

Sex

ALL

Min age

12 Years

Max age

—

Healthy volunteers

* Patients with pathologically confirmed selected tumor types (at site or centrally); * Mandatory availability of adequate human biological material (HBM); * Centrally performed confirmation of HBM adequacy in terms of quality and quantity for SPECTA downstream project requirements; * Age ≥ 12 years; * Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; * Written informed consent according to applicable legal and ethical requirements;

Primary outcome measure(s)

To establish a quality assured platform to improve the understanding of tumor biology and cancer patients care — 5 years
material (including imaging data) as well as patient-reported outcomes from patients with cancer diagnosis to support biospecimen-based translational research and biomarker discovery to improve the understanding of tumor biology and cancer patients care.

Trial sites (136)

Facility	City	Region	Status
Medical University Vienna - General Hospital AKH	Vienna	Austria	Recruiting
Onze Lieve Vrouw Ziekenhuis	Aalst	Belgium	Recruiting
ZAS Middelheim	Antwerp	Belgium	Recruiting
Hopitaux Universitaires - Institut Jules Bordet	Brussels	Belgium	Recruiting
Universitair Ziekenhuis Brussel	Brussels	Belgium	Recruiting
Cliniques Universitaires Saint-Luc	Brussels	Belgium	Recruiting
Universitair Ziekenhuis Gent	Ghent	Belgium	Recruiting
Pole Hospitalier Jolimont - Hopital Jolimont	Haine-Saint-Paul	Belgium	Recruiting
U.Z. Leuven - Campus Gasthuisberg	Leuven	Belgium	Recruiting
C.H.U. Sart-Tilman	Liège	Belgium	Recruiting
Centre Hospitalier Regional De La Citadelle	Liège	Belgium	Recruiting
CHU Site Sainte-Elisabeth-UCL Namur	Namur	Belgium	Recruiting
AZ Turnhout - Campus Sint Elisabeth	Turnhout	Belgium	Recruiting
CHU Mont Godinne - UCL Namur	Yvoir	Belgium	Recruiting
University Hospital Centre Zagreb	Zagreb	Croatia	Active Not Recruiting
Bank Of Cyprus Oncology Centre	Stróvolos	Cyprus	Recruiting
University Hospital Motol	Prague	Czechia	Recruiting
North Estonia Medical Centre - Mustamäe unit	Tallinn	Estonia	Recruiting
Centre Hospitalier Avignon	Avignon	France	Recruiting
CHRU de Besancon - Hopital Jean Minjoz	Besançon	France	Recruiting
Centre de Radiotherapie Pierre Curie	Beuvry	France	Recruiting
CHU de Bordeaux - Groupe Hospitalier Saint-Andre - Hopital Saint-Andre	Bordeaux	France	Recruiting
Institut Bergonie	Bordeaux	France	Recruiting
Centre Hospitalier - Boulogne Sur Mer	Boulogne-sur-Mer	France	Recruiting
CHU de Lyon - Hopital Louis Pradel	Bron	France	Recruiting
CHU Lyon - Hopital neurologique Pierre Wertheimer	Bron	France	Recruiting
Centre Francois Baclesse	Caen	France	Recruiting
Centre Hopitalier Intercommunal De Creteil	Créteil	France	Recruiting
Centre Georges-Francois-Leclerc	Dijon	France	Recruiting
CHU de Grenoble - La Tronche - Hôpital A. Michallon	Grenoble	France	Recruiting
Centre Hospitalier Departemental Vendee	La Roche-sur-Yon	France	Recruiting
Centre Oscar Lambret	Lille	France	Recruiting
CHRU de Lille	Lille	France	Recruiting
CHU de Lyon - Hopital Edouard Herriot	Lyon	France	Recruiting
Centre Léon Berard	Lyon	France	Recruiting
CHU de Lyon - Hopital Lyon Sud	Lyon	France	Recruiting
Assistance Publique - Hopitaux de Marseille - Hopital Nord	Marseille	France	Recruiting
Centre Hospitalier D'Annecy Genevois	Metz-Tessy	France	Recruiting
CHU Montpellier-Hopital Arnaud De Villeneuve	Montpellier	France	Recruiting
Institut du Cancer de Montpellier	Montpellier	France	Recruiting

+ 96 more sites — see the full list on the official registry below.

More European Organisation for Research and Treatment of Cancer - EORTC trials in Poland

Phase III Radium 223 mCRPC-PEACE III Active, not recruiting

Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib Active, not recruiting

Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma Active, not recruiting

Adjuvant Palbociclib in Elderly Patients With Breast Cancer Active, not recruiting

Study Assessing The "Best of" Radiotherapy vs the "Best of" Surgery in Patients With Oropharyngeal Carcinoma Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02834884 on ClinicalTrials.gov ↗ ← All trials in Poland